Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lupus: improving long-term prognosis.

A Doria1, C Briani

  • 1Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy. adoria@unipd.it

Lupus
|March 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disentangling Sources of Momentum Fluctuations in Xe+Xe and Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Light Long-Lived Particles in pp Collisions at sqrt[s]=13  TeV Using Displaced Vertices in the ATLAS Inner Detector.

Physical review letters·2024
Same author

Search for the Exclusive W Boson Hadronic Decays W^{±}→π^{±}γ, W^{±}→K^{±}γ and W^{±}→ρ^{±}γ with the ATLAS Detector.

Physical review letters·2024
Same author

Determination of the Relative Sign of the Higgs Boson Couplings to W and Z Bosons Using WH Production via Vector-Boson Fusion with the ATLAS Detector.

Physical review letters·2024
Same author

Studies of the Energy Dependence of Diboson Polarization Fractions and the Radiation-Amplitude-Zero Effect in WZ Production with the ATLAS Detector.

Physical review letters·2024
Same author

Combination of Searches for Higgs Boson Pair Production in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2024
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Improving long-term survival for systemic lupus erythematosus (SLE) patients requires early interventions. Strategies focus on preventing infections, atherosclerosis, and cancer, while managing disease activity and medication use to reduce complications.

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Immunology

Background:

  • Short- and medium-term survival in systemic lupus erythematosus (SLE) has improved significantly.
  • Long-term prognosis for SLE patients remains poor, primarily due to disease and treatment complications.
  • Current preventive strategies for infections, atherosclerosis, and cancer are often insufficient in SLE.

Purpose of the Study:

  • To identify key factors influencing long-term complications in systemic lupus erythematosus.
  • To propose strategies for improving long-term outcomes in SLE patients.
  • To emphasize the need for early and comprehensive management of SLE.

Main Methods:

  • Review of existing literature on SLE prognosis and complications.
  • Analysis of factors contributing to long-term morbidity and mortality in SLE.

Related Experiment Videos

  • Discussion of preventive strategies tailored to SLE patient profiles.

    • Main Results:

    • Severe SLE manifestations (e.g., glomerulonephritis, CNS involvement) significantly increase complication risk.
    • Use of corticosteroids and cyclophosphamide is associated with long-term complications.
    • Effective disease activity control with minimized drug dosage is crucial.

    Conclusions:

    • Early implementation of comprehensive preventive strategies is essential for improving long-term SLE prognosis.
    • Controlling disease severity and minimizing immunosuppressive drug use are critical.
    • Targeted interventions for high-risk individuals (e.g., antiphospholipid antibody-positive patients) are necessary.